IP Library Granted Patent US 7,071,159
Granted Patent B2
US 7,071,159 · App. 10/101,018 · Granted Jul 4, 2006

Inhibitor of vascular endothelial cell growth factor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,071,159
App. No.
10/101,018
Granted
Jul 4, 2006
Kind
B2
Abstract

The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.

Claims (4)

1. A method for inhibiting angiogenesis comprising the administration of a VEGF inhibitor protein in isolated form which comprises the amino acid sequence as set forth in SEQ ID NO:6.

2. A method for inhibiting angiogenesis comprising the administration of a VEGE inhibitor protein in isolated form which consists of the amino acid sequence as set forth in SEQ ID NO:6.

3. The method of claim 1 which further comprises administration of said VEGF inhibitor with a pharmaceutically acceptable carrier.

4. The method of claim 2 which further comprises administration of said VEGF inhibitor with a pharmaceutically acceptable carrier.

Assignments (3)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 28, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023861/0349 →